PoliticalRepoPoliticalRepo

United States · Bill · S

S. 3072 (116th)

SAVE Moms and Babies Act of 2019

referredUnited States· United States Congress· EN

Introduced

17 December 2019

Last action

17 December 2019 · Introduced

Status

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Sponsors

Cindy Hyde-Smith, Kevin Cramer, Roger Wicker, Rep. Inhofe, James M. [R-OK-1], Rick Scott, Steve Daines, Tom Cotton, Sen. Sasse, Ben [R-NE], James Lankford, Mike Rounds, Jerry Moran, Tim Scott, Sen. Rubio, Marco [R-FL], Sen. Braun, Mike [R-IN], John Kennedy, Sen. Loeffler, Kelly [R-GA], James Risch, Thomas Tillis, Marsha Blackburn, Sen. Enzi, Michael B. [R-WY], Sen. Blunt, Roy [R-MO], Deb Fischer, Mike Lee, Ted Cruz, Joni Ernst, John Thune, John Boozman, Josh Hawley, Sen. Portman, Rob [R-OH], John Cornyn, Sen. Graham, Lindsey [R-SC], John Barrasso, Todd Young, Mitch McConnell, John Hoeven, Dan Sullivan

Subjects

Healthcare

Source updated

5 December 2025

Healthcare

Official sourceDownload fileView documentsShare

Summary

Support And Value Expectant Moms and Babies Act of 2019 or the SAVE Moms and Babies Act of 2019 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner to also act as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 17 December 2019

    Introduced

    Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

    Source: IntroReferral

  2. 17 December 2019

    Introduced

    Introduced in Senate

    Source: IntroReferral

Votes

No vote records are attached yet.

Versions

Documents

3 official files

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.